GlobeNewswire Inc.··NaBioCryst Achieves Historic Profitability as ORLADEYO Revenue Surges 38%
BioCryst achieved historic profitability with ORLADEYO revenue surging 38% to $601.8 million. FDA approval for pediatric formulation and Astria acquisition expand HAE treatment portfolio.
BCRXFDA approvalprofitability